

Award Number: W81XWH-05-1-0142

TITLE: Functional Analysis of Human NF1 in Drosophila

PRINCIPAL INVESTIGATOR: Yi Zhong, Ph.D.

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory
Cold Spring Harbor, New York 11724

REPORT DATE: January 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-01-2007		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 Dec 2005 – 14 Dec 2006	
4. TITLE AND SUBTITLE Functional Analysis of Human NF1 in Drosophila				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0142	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yi Zhong, Ph.D. E-Mail: zhongyi@csih.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cold Spring Harbor Laboratory Cold Spring Harbor, New York 11724				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Neurofibromatosis type 1 (NF1) is characterized by benign but disfiguring skin tumors, pigmentation defects and learning disabilities, as well as increased risk of brain tumors. The NF1 tumor suppressor protein (neurofibromin) inhibits Ras, a protein that is overactive in a wide variety of human cancers. NF1 also controls levels of cyclic AMP, an important intracellular messenger involved in cell growth and learning. Over last year, we continue to examine the structural basis for its role in controlling multiple signal transduction pathways and roles in learning and memory formation. In addition to previously identified GAP related domain, we showed that the C-terminal is critical in mediating G protein dependent activation of adenylyl cyclase. We are now examining the functional roles of these two domains in learning and memory.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....4

Body.....4

Key Research Accomplishments.....5

Reportable Outcomes.....5

Conclusions.....5

References.....5-6

Figures and Legends.....7-9

Appendices.....10-21

Introduction

The NF1 protein has a central GTPase-activating protein-related domain (GRD), which catalyzes the intrinsic GTPase activity of Ras protein (Viskochil *et al.*, 1993). In NF1 patients as well as mammalian animal models, tumor and learning phenotypes observed have been attributed to hyperactivation of Ras (Declue *et al.*, 1992; Costa *et al.*, 2002). However, NF1 is also involved in the regulation of adenylyl cyclase (AC)/cAMP pathway, and this regulation is important for neuropeptide responses and learning (Guo *et al.*, 1997; Guo *et al.*, 2000). The major hypothesis of this proposal is that distinct regions of the NF1 protein control Ras/NF1 or Gs α /NF1 stimulated adenylyl cyclase (AC) activity, and that these regions can be readily identified by examining the phenotypes of mutated human gene expressed in *Drosophila* NF1 null mutants. We also propose that Gs α /NF1-activated AC pathway mediates learning or short-term memory but exerts no effect on long-term memory (LTM) while the Ras/NF1 activity is crucial in formation of LTM.

Body

Over the last year, we have mainly focused on identifying the region of the NF1 protein molecule that is responsible for mediating Gs α /NF1-activated AC activity. The functions of NF1-GRD have been extensively characterized in both vertebrates and flies. However, the NF1 region that is responsible for mediating Gs α /NF1 activation of AC has yet to be identified even though this pathway has been shown to be critical in mediating neurotransmission in both vertebrates and flies, in controlling development of body size, in mediating learning in *Drosophila* (Guo *et al.*, 1997, 2000; The *et al.*, 1997; Tong *et al.*, 2002; Dasgupta *et al.*, 2003). For this purpose, we have mainly examined effects of various deletions to localize the region that can affect body size and AC activation.

We expressed the human NF1 gene (hNF1) as well as deletions introduced into the gene recently by our lab in flies (tasks 1b-g) with no endogenous NF1 expression to assay their effects on body size and AC activation. In regards to AC activation, we found that both serotonin and histamine can induce cAMP production mediated by the Gs α /NF1 pathway (fig. 1A). In addition, epidermal growth factor (EGF) can stimulate AC through the Ras/NF1 pathway (fig. 1B) and this mediation is independent of the Gs α /NF1 pathway (fig. 1C). These results indicate that NF1 is involved in two independent pathways that lead to the activation of AC, with the stimulation of different signaling molecules. With this paradigm established, we further tested the effects of different hNF1 deletion mutations our lab created have on the stimulation event. We discovered that the GRD region, and therefore the Ras/NF1 pathway, is necessary and sufficient in mediating the stimulating effect of EGF on AC activity, while sequences toward the C-terminal are essential for the Gs α /NF1-dependent stimulation of cAMP production (fig. 2A). The C-terminal is also crucial for governing the body size, and this is also independent of the GRD (fig. 2B). This represents the first demonstration for functions of an NF1 region that is outside of the GRD and that its function is independent of the GRD.

In the next period, we would like to examine effects of the GRD and C-terminal regions on learning and memory and then we would like to determine more precisely on the motif that is involved in mediating AC activation.

Key Research Accomplishments

We have identified distinct functionality conferred by different portion of the NF1 protein and revealed for the first time NF1 C-terminal region being necessary and sufficient for mediating Gsa/NF1-dependent AC activation as well as governing body size.

Reportable Outcomes

The effort has resulted one publication as listed below:

Hannan F, Ho I, Tong JJ, Zhu Y, Nurnberg P, Zhong Y. (2006) Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. *Hum Mol Genet* 15(7):1087-98.

Conclusion

Through body size measurement and AC activity assay, we have identified the C-terminal of NF1 as the structure mediating Gsa/NF1 dependent AC activation. In the search of NF1 C-terminal function, we have also revealed a separate NF1-dependent pathway that mediates growth factor stimulation of AC. This study represents the first demonstration of functions for a domain outside of the GRD. The data presented above can be summarized in a signal transduction model (fig. 3). Our discovery should contribute to the understanding of structure and functions of NF1.

References

Costa, R.M., Federov, N.B., Kogan, J.H., Murphy, G.G., Stern, J., Ohno, M., Kurcherlapati, R., Jacks, T., and Silva, A.J. (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. *Nature*, 415, 526-530.

Dasgupta, B. Dugan, L.L. and Gutmann, D. H. (2003) The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. *J Neurosci.* 23, 8949-54.

DeClue, J.E., Heefelfinger, S., Benvenuto, G., Ling, B., Li, S., Rui, W., Vass, W.C., Viskochil, D., and Ratner, N. (1992) Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. *Cell*, 69, 265-273.

Guo, H.-F., The, I., Hannan, F., Hariharan, I. K., Bernards, A., and Zhong, Y. (1997) Requirement of *Drosophila* NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. *Science* 276: 795-798.

Guo, H.-F., Tong, J., Hannan, F., Luo, L. and Zhong, Y. (2000) A neurofibromatosis-1-regulated pathway is required for learning in *Drosophila*. *Nature*, 403, 895-898.

The, I., Hannigan, G. E. Reginald, S., Zhong, Y. Gusella, J. F., Hariharan, I. K. and Bernards, A. (1997) *Drosophila NF1* acts in growth regulation and PKA-mediated signaling. *Science* 276: 791-794.

Tong, J., Hannan, F., Zhu, Y., Bernards, A. and Zhong, Y. (2002) Neurofibromin regulates G Protein-Stimulated adenylyl cyclase activity. *Nature Neuroscience*, 5, 95-96.

Viskochil, D., White, R., and Cawthon, R. (1993) The neurofibromatosis type 1 gene. *Annu. Rev. Neurosci.*, 16, 183-205.

Appendices

Hannan F, Ho I, Tong JJ, Zhu Y, Nurnberg P, Zhong Y. (2006) Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. *Hum Mol Genet* 15(7):1087-98.




Figure 1. AC stimulation mediated by two independent signaling pathways while both involving NF1. Serotonin (A) and histamine (B) stimulate cAMP production via Gsα/NF1 pathway; this is independent of the Ras pathway as Ras mutants do not disrupt this stimulation. (C) EGF induces AC activity and it's mediated by Ras/NF1 pathway, as evidenced by the abolishment of this stimulated by either NF1 or Ras mutations. (D) The EGF-Ras-NF1 pathway that leads to AC stimulation is independent of the Gsα/NF1 pathway as Gsα mutant showed no discernable effect on EGF stimulation.




Figure 2. Distinct regions of the NF1 protein confer different functions in *Drosophila*. **(A)** The GRD region is necessary and sufficient for mediating EGF signaling for AC activation, while C-terminal region is essential for serotonin and histamine's stimulation of AC activity. **(B)** Unlike the GRD region, C-terminal is able to significantly rescue the body size defect compared to the null mutant *Nf1^{P2}*.




Figure 3. AC can be activated by at least three distinct pathways: First, a novel NF1/Ras-dependent pathway stimulated by growth factors such as EGF and TGF- α that activates an unidentified AC (AC-X), and does not involve Gas; secondly, an NF1/Gas-dependent pathway, acting through Rutabaga-AC (Rut-AC), stimulated by serotonin and histamine, and possibly PACAP38 (Guo *et al.*, 1997), that does not require Ras; thirdly, a classical NF1-independent pathway, involving Gas but not NF1 or Ras, stimulated by FMRFamide and dopamine that activates an unidentified AC (AC-Y).

Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras

Frances Hannan^{1,2,†}, Ivan Ho^{1,3,†}, James Jiayuan Tong^{1,4,5}, Yinghua Zhu¹, Peter Nurnberg⁶ and Yi Zhong^{1,*}

¹Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA, ²New York Medical College, Valhalla, NY 10595, USA, ³Graduate Program in Genetics and ⁴Graduate Program in Neurobiology and Behavior, State University of New York at Stony Brook, NY 11794, USA, ⁵Biophysics and Physiology, University of California, Irvine, CA 92697, USA and ⁶Cologne Center for Genetics and Institute for Genetics, University of Cologne, 50674 Cologne, Germany

Received December 8, 2005; Revised and Accepted February 7, 2006

Neurofibromatosis type I (NFI) is a common genetic disorder that causes nervous system tumors, and learning and memory defects in humans, and animal models. We identify a novel growth factor stimulated adenylyl cyclase (AC) pathway in the *Drosophila* brain, which is disrupted by mutations in the epidermal growth factor receptor (EGFR), neurofibromin (NF1) and Ras, but not $G\alpha_s$. This is the first demonstration in a metazoan that a receptor tyrosine kinase (RTK) pathway, acting independently of the heterotrimeric G-protein subunit $G\alpha_s$, can activate AC. We also show that $G\alpha_s$ is the major $G\alpha$ isoform in fly brains, and define a second AC pathway stimulated by serotonin and histamine requiring NF1 and $G\alpha_s$, as well as a third, classical $G\alpha_s$ -dependent AC pathway, which is stimulated by Phe-Met-Arg-Phe-amide (FMRamide) and dopamine. Using mutations and deletions of the human NF1 protein (hNF1) expressed in *Nf1* mutant flies, we show that Ras activation by hNF1 is essential for growth factor stimulation of AC activity. Further, we demonstrate that sequences in the C-terminal region of hNF1 are sufficient for NF1/ $G\alpha_s$ -dependent neurotransmitter stimulated AC activity, and for rescue of body size defects in *Nf1* mutant flies.

INTRODUCTION

Mutations in the human *NFI* gene are characterized by benign but disfiguring tumors of the peripheral nervous system, as well as increased incidence of malignant peripheral nerve sheath tumors and central nervous system tumors (1). About 40% of children with NFI exhibit learning deficits (2,3), and mouse models of NFI recapitulate both the tumor and learning phenotypes (4–6). In *Drosophila*, *Nf1* mutations affect circadian rhythms (7), body size (8), responses to neuropeptides (9) and olfactory learning (10). Thus, the NF1 protein is essential for normal neural development and plasticity in both vertebrates and invertebrates.

Gaining insights into the molecular mechanisms of NF1 function requires the identification of cellular signal

transduction pathways that are disrupted by *NFI* mutations. Biochemical and genetic analysis in mammals and *Drosophila* has revealed that NF1 inhibits Ras activity (4–7), and regulates AC activity and cAMP levels (8–13). The NF1 protein has a central GTPase activating protein (GAP)-related domain (GRD), which catalyzes the intrinsic GTPase activity of Ras (14). Many of the tumor phenotypes and learning deficits observed in NFI patients and animal models have been attributed to hyperactivation of Ras, that is observed, for example, in Schwann cells and mast cells (15–18). However, the NF1-regulated AC/cAMP pathway is important for controlling neuropeptide responses (9) and learning (10) in flies, as well as neuropeptide-stimulated AC activity in both flies and mammals (12,13). The NF1-dependent activation of AC versus downregulation of Ras may therefore

*To whom correspondence should be addressed. Tel: +1 5163678811; fax: +1 5163678000. Email: zhongyi@cshl.edu

†The authors wish it to be known that, in their opinion, the first three authors should be considered as joint First Authors.

have important phenotypic consequences, but the molecular mechanism, whereby NF1 regulates AC activity has not yet been determined.

The product of the *Drosophila Ras1* gene is functionally equivalent to vertebrate H-Ras, K-Ras, or N-Ras that are mutated in 30% of human cancers (19). Ras signaling is down-regulated by the activity of GAPs, which catalyze the hydrolysis of Ras-GTP to Ras-GDP. Five genes are reported to encode Ras-specific GAPs in *Drosophila* (20). The *Gap1* and *Nf1* genes each encode a GRD that can bind with Ras and catalyze GTPase activity (8,21), however, the *Gap1* protein requires regions outside the GRD to achieve full catalytic activity (22). Guanine exchange factors (GEFs) promote the exchange of GDP for GTP to activate Ras, thereby enabling interaction with downstream effectors such as Raf-1 and PI3 kinase (23,24). GEF activation of Ras is controlled by signaling through RTKs such as *sevenless* and the *Drosophila* EGFR (25–27). Classical genetic studies in *Drosophila* identified the *sevenless* RTK and its GEF *son-of-sevenless* (SOS) through their effect on eye development (25). Mutations in the *Gap1*, *Ras1*, *sevenless* and *EGFR* genes also lead to defects in eye development and embryo patterning (21,25,26). The *Nf1* gene product does not perform a critical function in either of these pathways, probably owing to redundancy of *Gap1* and NF1 activity, as *Gap1;Nf1* double mutants are lethal (8).

Our study identifies three distinct AC signaling pathways in the *Drosophila* brain, including a novel growth factor activated NF1/Ras-dependent AC, that remarkably does not require $G\alpha_s$, as well as two separate neurotransmitter-stimulated AC pathways, one requiring NF1 and $G\alpha_s$, whereas the other requires $G\alpha_s$ alone. Analysis of the effect of human NF1 mutations and partial deletions, expressed in flies with no NF1, shows that separate domains of NF1 control the different AC pathways. In particular, we show that RasGAP activity of NF1 is necessary for Ras/NF1-dependent AC signaling but not NF1/ $G\alpha_s$ -dependent AC signaling, whereas part of the C-terminal region is sufficient for NF1/ $G\alpha_s$ -dependent AC signaling and regulation of body size.

RESULTS

NF1 and Ras activate AC

The first indication that Ras may activate AC was shown by incubation of human H-Ras with *Drosophila* head membrane extracts to produce a dose- and time-dependent increase in AC activity, as measured by increases in cAMP levels (Fig. 1A). AC activity was also stimulated by human K-Ras (Fig. 1B), but not Rab3a (Fig. 1C), suggesting that activation is specific to the Ras family of small GTPases, and not because of depletion of GTP or other factors. Secondly, this stimulation was shown to be NF1-dependent, as it was eliminated in *Nf1* homozygous null mutant flies, *Nf1^{P1}* and *Nf1^{P2}* (Fig. 1D), which do not express any detectable NF1 protein (8). Furthermore, acute expression of a wild-type *Nf1* transgene in the mutant background, controlled by a heat-shock promoter (*hsNf1*; *Nf1^{P2}*), was able to fully restore the H-Ras-stimulated AC activation to wild-type levels (Fig. 1D). The acute nature

of the response to NF1 indicates that this is not a developmental effect, and that NF1 is a critical component of the Ras-stimulated AC activity.

To further define the role of NF1 in Ras-stimulated AC activity we examined the effect of a purified GST-fusion protein containing an NF1-GRD fragment that retains GAP activity (28). Significant increases in AC activity, measured by increased cAMP levels, were shown in wild-type extracts treated with NF1-GRD fusion protein in the absence of H-Ras (Fig. 1E). This effect is specific to the GAP activity of the NF1-GRD fragment, as it is abolished in two NF1-GRD mutants (R1391S; K1419Q; Fig. 1E) with reduced GAP activity, found in NF1 patients (28–30). The NF1-GRD fragment was also unable to stimulate AC activity above control levels in *Ras^{e2F/+}* heterozygotes (Fig. 1F), which have an inactivating mutation in the Switch I region of Ras (25) that normally activates Ras and interacts with downstream effectors. This suggests that levels of active Ras in these heterozygous flies are insufficient to stimulate AC activity, and that endogenous *Drosophila* Ras can interact with human NF1.

Growth factors stimulate the novel NF1/Ras-dependent AC pathway

To evaluate the functional significance of this novel pathway, we developed an assay to examine effects of neurotransmitters and growth factors on Ras stimulation of AC activity *in vivo*. Significant stimulation of AC activity was observed in wild-type larval brains treated with EGF or TGF α (Fig. 2A and B). Stimulation of AC activity was abolished in *Drosophila* EGFR mutants (Fig. 2A and B), including the *Egfr^{tl}* hypomorphic mutant and the *Df(2R)Egfr^{18/+}* deficiency heterozygote (31), demonstrating that these growth factors are acting directly on the *Drosophila* EGFR to stimulate AC activity. The stimulation of AC activity by growth factors is also abolished in both *Nf1* homozygous null mutants and in *Ras^{e1B/+}* and *Ras^{e2F/+}* heterozygotes (Fig. 2A and B). The *Ras^{e1B}* mutation affects the Switch II activator/effector domain of Ras (25) that contacts R1391S of NF1. Again, this demonstrates a requirement for both Ras and NF1 in the stimulation of AC activity.

To ensure that there is no crosstalk between EGFR and $G\alpha_s$, we assayed growth factor stimulation of AC in *Gsa^{B19}* hypomorphic mutants (32). Normal levels of stimulation of AC activity by both EGF and TGF α growth factors were seen in larval brains of *Gsa^{B19}* mutants (Fig. 2C and D), consistent with the fact that the *Drosophila* EGFR does not contain the juxtamembrane domain that facilitates crosstalk in vertebrate EGFRs (33). Stimulation by GTP γ S is very low in the *Gsa^{B19}* mutants (Fig. 2C and D), indicating that $G\alpha_s$ is indeed the major stimulatory G-protein in larval brains. Control treatment of larval brains with insulin did not stimulate AC activity (Fig. 2E). Thus, stimulation of AC by both EGF and TGF α growth factors require EGFR, Ras and NF1, but does not involve $G\alpha_s$. The identified ligands for the *Drosophila* EGFR are members of the TGF α family (33). This suggests that stimulation of the Ras/NF1-dependent AC pathway in flies may be activated by binding of endogenous ligands to the EGFR.




Figure 1. NF1 and Ras activate AC. (A) Significant increases in AC activation were observed after 10 min to 60 min incubation with human H-Ras at different concentrations ($P < 0.05$; $n = 3$). (B) Both H-Ras and K-Ras stimulate AC activity (1 mM; $t = 30$ min; $n = 4$). (C) Rab3a does not stimulate AC activity (1 mM; $t = 30$ min; $n = 4$). (D) H-Ras stimulation of AC was eliminated in *Nf1^{P1}* and *Nf1^{P2}* mutant flies, and restored by heat-shock induced expression of a fly *Nf1* transgene in *hsNf1;Nf1^{P2}* flies (1 mM; $t = 60$ min; $n = 8, 8, 8, 3$). (E) A human NF1-GRD-GST fusion protein is able to stimulate AC, in the absence of H-Ras. There was no stimulation by GST alone, or by NF1-GRD-GST missense mutants, R1391S and K1419Q, that reduce RasGAP activity (1 mM; $t = 30$ min; $n = 4$). (F) Stimulation by human NF1-GRD-GST was abolished in *Ras^{E2F/+}* heterozygotes (1 mM; $t = 30$ min; $n = 2$). (A-F) Values are mean \pm SEM (** $P < 0.05$; *** $P < 0.01$).

Neurotransmitters stimulate two additional AC pathways

We next examined the effects of neurotransmitters and neuromodulators that are ligands for G-protein coupled

receptors. Stimulation of AC by the neuropeptide FMRFamide, and by the neurotransmitter dopamine was not affected in *Nf1* null mutants or *Ras/+* heterozygotes, however, it was abolished in *Gsa^{B19}* mutants that disturb the classical G-protein signaling




Figure 2. Growth factors stimulate the novel NF1/Ras-dependent AC pathway. (A) AC activity was significantly increased by treatment of larval brains with 2 mM EGF ($n = 18$). This stimulation was abolished in EGFR mutants, *Egfr¹¹*, and heterozygotes, *Df(2R)Egfr¹⁸/CyO*; in *Nf1* null mutants, *Nf1^{P1}* and *Nf1^{P2}*; and in *Ras* heterozygotes, *Ras^{e2F}/TM3* and *Ras^{1B}/TM3* ($n = 4$). (B) Stimulation of AC by 2 mM TGF α was similarly abolished in the *Egfr¹¹* mutant, *Nf1* mutants and *Ras* heterozygotes ($n = 4$). Stimulation of AC by 2 mM EGF (C) or TGF α (D) is not affected in a hypomorphic *Gsa* mutant, *Gsa^{B19}*, whereas stimulation by 20 mM GTP γ S is perturbed ($n = 3$). (E) There was no stimulation of AC by 2 mM insulin ($n = 3$). (A–E) Values are mean \pm SEM (** $P < 0.01$; *** $P < 0.005$).

pathway (Fig. 3A and B). Thus, alterations in NF1 or Ras that disrupt growth factor-dependent stimulation of AC activity (Fig. 2A and B), do not affect classical G-protein dependent stimulation of AC.

In contrast, stimulation of AC by the neurotransmitters serotonin and histamine was disrupted in both *Nf1* null mutants and *Gsa^{B19}* mutants but not in *Ras*/+ heterozygotes (Fig. 3C and D), demonstrating an NF1/*Gsa*-dependent pathway for stimulation of AC activity that does not require Ras. A number of other neurotransmitters and neuromodulators had no effect on AC activity, including the neuropeptide pituitary AC activating polypeptide neuropeptide (PACAP38) (data not shown), suggesting that there are no receptors for these ligands in the larval brain.

Human *NF1* mutations affect MAPK activity in *Nf1* mutant flies

To address the possibility that NF1-dependent activation of AC versus downregulation of Ras activity is responsible for the

variety of phenotypes seen in NFI patients and animal models, we examined clinically relevant missense mutations from NFI patients that are scattered throughout the length of the hNF1 protein (34–36), as well as deletions of hNF1. We report here the effect of expressing hNF1 containing four different missense mutations and five partial deletions (Fig. 4A) in the *Drosophila Nf1* mutant background, which were assayed for their effect on growth factor and neurotransmitter-stimulated AC activity. The mutations chosen for this study occur in multiple patients and affect conserved amino acids (Table 1). When assayed in yeast, the GRD domain mutants R1391S and K1423E drastically reduce GAP activity (29,30,37), whereas the R1276P mutant completely abolishes GAP activity (38). Transcription of UAS-*hNF1* transgenes in flies was controlled using Gal4 drivers (39), including the one that is expressed globally (*e22c-Gal4*); (40) and a nervous system specific driver (*elav-Gal4*); (41). Assays were performed on flies that carry one copy of the normal or mutant UAS-*hNF1* transgene and one copy of the Gal4 driver in the *Nf1* mutant background (Fig. 4B and C), showing that




Figure 3. Neurotransmitters and neuromodulators stimulate two additional AC pathways. FMRFamide and dopamine stimulate $G\alpha_s$ -dependent AC: activation of AC by 200 nM FMRFamide (A) and dopamine (B) is disrupted in $G\alpha_s$ mutants, but not in *Nf1* mutants or *Ras* heterozygotes ($n = 3-4$). Serotonin and histamine however, stimulate NF1/ $G\alpha_s$ -dependent AC: activation of AC by 200 nM serotonin (C) and histamine (D) is disrupted in $G\alpha_s$ and *Nf1* mutants but not in *Ras* heterozygotes ($n = 4$). (A-D) Values are mean \pm SEM (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.005$).

hNF1 functions in *Drosophila*, and defining two separate domains that mediate activation of distinct AC pathways.

Phosphorylation of mitogen-activated protein kinase (MAPK) is elevated in *Drosophila Nf1* mutants because of increased Ras activity (7). We first showed that normal hNF1 is able to inhibit Ras by showing that phospho-MAPK is reduced to wild-type levels when hNF1 (two independent lines; hNF1a and hNF1b) is expressed in *Nf1* mutant flies under control of the *e22c*-Gal4 global driver (Fig. 4D and E). As expected, mutant hNF1s with defective RasGAP activity (R1276P, R1391S, K1423E) or lacking the GRD (Δ GRD2, Cterm) cannot reduce phospho-MAPK levels (Fig. 4E). The GRD fragments alone (GRD1, GRD2) were able to restore phospho-MAPK to wild-type levels, and the L847P mutation did not affect the RasGAP activity of full-length hNF1 (Fig. 4E).

Human *NF1* mutations affect AC activity in *Nf1* mutant flies

We then demonstrated that the RasGAP activity of hNF1 was required for growth factor-stimulated AC activity, by expressing the mutant hNF1s or deletions under control of the nervous system-specific *elav*-Gal4 driver for larval brain assays. Mutant hNF1s with defective RasGAP activity, or lacking the GRD, did not respond to EGF stimulation (Fig. 5A and C). However, the L847P mutant and the GRD fragments responded normally to EGF (Fig. 5B and C), indicating that the RasGAP activity of the GRD is indeed required for growth factor-stimulated NF1/Ras-dependent AC activity.

We next examined serotonin- and histamine-stimulated AC activity to see whether RasGAP activity of NF1 was required




Figure 4. Missense mutations and deletions of human NF1 modulate *Drosophila* MAPK activity. (A) Position of four hNF1 missense mutations, and size of five hNF1 deletion constructs, that have been expressed and analyzed in *Drosophila Nf1* null mutants (CSR, Cys-Ser-rich domain; GRD, GAP-related domain; LRD, Leu-rich domain). Crosses required to generate F1 progeny expressing UAS-hNF1 mutants or deletion constructs under control of the nervous system specific *elav*-Gal4 driver (B) on the X chromosome or the globally expressing *e22c*-Gal4 driver (C) on the second chromosome. (D) Representative western blot of head extracts from flies expressing normal and mutant hNF1s and deletions, probed with anti-phospho-MAPK then stripped and re-probed with anti-MAPK antibodies. (E) Levels of phospho-MAPK versus total MAPK levels in flies expressing hNF1 mutants and deletions, normalized to K33 wild-type (+) control values (see Materials and Methods). (D and E) Expression is under control of the *e22c*-Gal4 driver. (E) Values are mean \pm SEM (**P* < 0.05; ***P* < 0.01; *n* = 4–6).

for the NF1/Gα_s-dependent AC pathway. Stimulation of AC was normal for mutant hNF1s with or without RasGAP activity (Fig. 5A and B), indicating that NF1/Gα_s-dependent AC activity does not require RasGAP activity. Consistent with this, the GRD fragments alone were not sufficient to restore NF1/Gα_s-dependent AC activity (Fig. 5C). We then asked

whether any other region of NF1 is required for NF1/Gα_s-dependent AC activity. Constructs lacking the GRD (ΔGRD2, Cterm) were able to restore neurotransmitter-stimulated AC activity (Fig. 5C), demonstrating that sequences in the C-terminal region, common to ΔGRD2 and Cterm (Fig. 4A), are essential for NF1/Gα_s-dependent AC activity.

Table 1. Human *NF1* missense mutations expressed in *Drosophila*

Mutation ^a	Amino acids conserved ^b	Effect	Mutagenic primer ^c	Site added	Number of lines
Human NF1	—	Normal	—	—	4
L847P (2)	gFLc <u>AL</u> GGVC	Not known	5'pTGGAGGCACACTCCCCAGGT <u>GCACAAAGGAAGCCAGTC3'</u>	<u>Apa</u> LI	2
R1276P (1)	MQTLFR <u>GN</u> SL	Abolish GAP activity	5'pGGCCAAGCTGTTGCCCGGAA GAGAGTCTGC3'	<u>Sma</u> I	1
R1391S (1)	mFLR <u>FIN</u> PAI	Reduce GAP activity	5'pGGCAGGATTGATA <u>AA</u> GCTTAG GAACATGGC3'	<u>Hind</u> III	2
K1423E (5)	kLM <u>SK</u> ILQsI	Reduce GAP activity	5'pGATTGGCAATACTCTGCA <u>AG</u> AT <u>CTCGGACATTA</u> ACTTC3'	<u>Bgl</u> II	3

^aNumber of clinical occurrences is bracketed (30,35,38,39).

^bAmino acids that are identical in human, mouse and fly are capitalized and the mutated amino acid is underlined.

^cRestriction site added is underlined and mutated bases are in bold. Primers are complementary to the coding strand of hNF1 and 5'-phosphorylated.

Human *NF1* mutations also affect body size in *Nf1* mutant flies

In order to confirm the physiological relevance of the NF1/ $G\alpha_s$ -dependent AC activity, and to verify that RasGAP activity is not required, we examined the effect of expressing the hNF1 mutants and deletions on the small body size phenotype previously seen in adult flies (8). This phenotype can be rescued by supplying cAMP, but not by decreasing Ras activity (8). We first showed that normal hNF1 is able to rescue the small body size of males and females using both *elav-Gal4* and *e22c-Gal4* drivers (Fig. 5D). All four clinically relevant missense mutants, including those with defective RasGAP activity, are able to rescue body size just as effectively as normal hNF1 (Fig. 5E) and neither of the GRD fragments was able to rescue body size (Fig. 5F). Thus, the RasGAP activity of hNF1 is not required for rescue of body size. Both the GRD deletion and C-terminal fragment were effective at rescuing body size, but not the N-terminal fragment (Fig. 5F). The L847P mutation in the region upstream of the GRD can still rescue MAPK activity (Fig. 4D and E), AC activity (Fig. 5B) and small body size (Fig. 5E). This mutation may affect other aspects of NF1 function such as regulation or localization, rather than activity.

DISCUSSION

Three separate pathways for AC activation defined in this study are depicted in Figure 6. First, a novel pathway for AC activation, downstream of growth factor stimulation of EGFR that requires both Ras and NF1, but not $G\alpha_s$. Secondly, an NF1/ $G\alpha_s$ -dependent AC pathway operating through the Rutabaga-AC (Rut-AC) and stimulated by serotonin and histamine, as observed here in the larval brain. The Rut-AC pathway may also be stimulated by PACAP38 at the larval neuromuscular junction and in adult heads as shown in previous studies (9,10,12). Thirdly, a classical G-protein coupled receptor-stimulated AC pathway (42) operating through $G\alpha_s$ alone. The AC activated by NF1/Ras (AC-X), or $G\alpha_s$ (AC-Y), has not yet been identified.

This study shows for the first time that Ras can stimulate AC in an NF1-dependent manner in higher organisms, via an RTK-coupled pathway that is independent of the $G\alpha_s$

G-protein. The functionality of human NF1 in the fly system, and the high degree of identity between human and fly NF1 (60%); (8), suggests that similar pathways for AC activation may also operate in mammals. Previous studies failed to detect stimulation of AC by Ras in cultured vertebrate cell lines (43), and in *Xenopus* oocytes (44), however, these cell types may not contain sufficient NF1 to support NF1/Ras-dependent AC activation. This is consistent with our observation that levels of both Ras and NF1 are critical for stimulation of AC activity in adult head membranes. The reported EGF activation of AC in cardiac myocytes and other tissues requires both $G\alpha_s$, and the juxtamembrane domain of the EGFR (45,46), which is not present in the *Drosophila* EGFR (33).

Our experiments with human NF1 mutants show that the GRD domain and the RasGAP activity of NF1 are both necessary and sufficient for growth factor-stimulated NF1/Ras-dependent AC activity. We also conclude that C-terminal residues downstream of the GRD are critical for both body size regulation and neurotransmitter-stimulated NF1/ $G\alpha_s$ -dependent AC activity, thus defining for the first time a region outside the GRD that contributes to this pathway. Interestingly, expression of a human NF1 GRD fragment in *Nf1*^{-/-} astrocytes results in only partial restoration of NF1-mediated increases in cAMP levels in response to PACAP (13). Thus, regions outside the GRD also seem to be necessary for activation of AC in these mammalian cells.

Thus, NF1, while being a negative regulator of Ras, is also actively involved in stimulation of AC activity. Moreover, it regulates AC activity through at least two different mechanisms, one of which depends on the RasGAP activity of NF1. The multifunctional nature of the NF1 protein illuminates its importance in nervous system development, tumor formation and behavioral plasticity, and may also explain the wide range of clinical manifestations in neurofibromatosis type I.

MATERIALS AND METHODS

Drosophila melanogaster media, strains and heat-shock conditions

Flies were raised at room temperature (22–24°C) on standard cornmeal medium. The *Nf1* mutants *Nf1*^{P1} and *Nf1*^{P2}, together with the parental K33 line and *hsNf1*;*Nf1*^{P2} flies were obtained




Figure 5. Separate domains of human NF1 mediate activation of different AC pathways. (A) EGF does not stimulate AC activity in flies expressing RasGAP-defective mutant hNF1s (R1276P, R1391S, K1423E), compared with K33 (control) flies or flies expressing normal hNF1, however, serotonin- and histamine-stimulated AC activity is fully restored. (B) Stimulation of AC activity by EGF, serotonin and histamine is restored in flies expressing the L847P hNF1 mutation. (C) EGF stimulated AC activity is restored in lines expressing GRD fragments (GRD1; GRD2), but serotonin- and histamine-stimulated AC activity is absent. Conversely, serotonin and histamine, but not EGF, stimulate AC activity in flies expressing a GRD deletion (ΔGRD2) or a C-terminal fragment (Cterm) alone. (D) Pupal length is increased in flies expressing normal hNF1 using *elav-Gal4* or *e22c-Gal4* drivers compared with *Nf1* mutant and K33 wild-type (+) controls expressing driver alone. (E) Pupal length is also increased in flies expressing all four missense mutations (L847P, R1276P, R1391S or K1423E) compared with *Nf1* mutants expressing driver alone. (F) Pupal length is not increased in flies expressing GRD fragments (GRD1; GRD2) or an N-terminal fragment (Nterm), however it is increased in flies expressing a GRD deletion (ΔGRD2) or a C-terminal fragment (Cterm). (A–C) Expression is under control of the *elav-Gal4* driver, values are mean ± SEM (***P* < 0.01; ****P* < 0.001; *n* = 4). (D–F) Expression is under control of the *e22c-Gal4* driver except where otherwise indicated, values are mean ± SEM (**P* < 0.01; ***P* < 0.001; *n* > 50).




Figure 6. AC can be activated by at least three distinct pathways: First, a novel NF1/Ras-dependent pathway stimulated by growth factors such as EGF and TGF α that activates an unidentified AC (AC-X), and does not involve G α_s ; secondly, an NF1/G α_s -dependent pathway, acting through Rutabaga-AC (Rut-AC), stimulated by serotonin and histamine, and possibly PACAP38 (see discussion), that does not require Ras; thirdly, a classical NF1-independent pathway, involving G α_s but not NF1 or Ras, stimulated by FMRFamide and dopamine that activates an unidentified AC (AC-Y).

from A. Bernards (Massachusetts General Hospital, Boston, MA, USA). K33 flies used as wild-type controls have a P-element inserted 1.5 kb downstream of the *Nf1* locus, that was mobilized to generate the *Nf1*^{P1} and *Nf1*^{P2} null mutant alleles (8). *Nf1*^{P1} deletes most of the *Nf1* gene and several downstream genes from the *Enhancer of Split* locus, whereas *Nf1*^{P2} carries a P-element insertion within the first intron of the *Nf1* gene, and neither allele produces any detectable NF1 protein (8). Heat-shock induction of NF1 was performed at 35°C for 2 h, then flies were rested at 21–23°C for 1 h. The *Ras*^{e1B} and *Ras*^{e2F} mutants are from the *Drosophila* Stock Center (Bloomington, IA, USA). Each has an amino acid substitution in either the Switch II or Switch I effector domains, respectively (25). Both affect Ras activation and binding to downstream effectors and are homozygous lethal. The EGFR mutants are also from the Bloomington Stock Center. *Egfr*¹¹ is a hypomorph and *Df(2R)Egfr*¹⁸ is a homozygous lethal deficiency (31). *Ras*^{e1B}, *Ras*^{e2F} and *Df(2R)Egfr*¹⁸ heterozygotes carrying a balancer (wild-type) chromosome (*TM3* or *CyO*; 47) were used for all assays. *Gs* α ^{B19} is a hypomorphic mutant (32) provided by M. Forte (Vollum Institute, Portland, OR, USA). Gal4 driver lines: *elav-Gal4*/*Nf1*^{P1} (7) was obtained from A. Sehgal (University of Pennsylvania, Philadelphia, PA, USA); *e22c-Gal4* (40) was from N. Perrimon (Harvard Medical School, Boston, MA, USA). White^{118(isoCJ1)} (48) was obtained from T. Tully (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA).

Adult head AC activity assay

The AC activity assay was performed as detailed here, essentially as described by Livingstone (49). About 20 heads/genotype of adult male *Drosophila*, anaesthetized by chilling, were

homogenized in 850 μ l lysis buffer (25 mM Tris–acetate buffer at pH 7.5, 1 mM dithiothreitol, 0.01 mg/ml aprotinin and 0.01 mg/ml pepstatin) using a glass pestle. Membranes were recovered by centrifugation at 178 000g for 10 min at 4°C, then re-suspended in 800 μ l lysis buffer on ice. Protein concentration (typically 1.5–2.5 mg/ml) was determined using the Bradford Protein Assay (BioRad), and adjusted to 1 mg/ml. Fifty microlitres of 2 \times assay buffer (50 mM Tris–acetate buffer at pH 7.5, 20 mM MgCl₂, 2 mM dithiothreitol, 10 mM creatine phosphate, 200 units/ml creatinine kinase, 0.1 mM cAMP at pH 7.5, 0.2 mg/ml bovine serum albumin, 0.02 mg/ml aprotinin, 0.02 mg/ml pepstatin and fresh 0.2 mg/ml PMSF) was added to 20 μ l samples in glass vials on ice. Twenty microlitres Ca²⁺ solution (2.5 mM CaCl₂, 0.25 mg/ml calmodulin and 5 mM EGTA) was then added to samples, bringing the final [Ca²⁺] to 10⁻⁷ M (as calculated using MaxChelator v1.31). Samples were equilibrated at 25°C for 2 min, then H-Ras, K-Ras, Rab3a or GST-NF1-GRD were added (1 nM to 1 μ M) to the membrane preparation. After 5–60 min incubation at 25°C, 10 μ l radioactive substrate (10 μ Ci α -P³²-ATP, 2 mM ATP) was added, and each sample was incubated at 25°C for a further 10 min. Reactions were stopped by adding 150 μ l of stop solution (33 pCi/ μ l ³H-cAMP, 1.3% SDS, 30 mM ATP, 0.9 mM cAMP at pH 7.5). Then 750 μ l water was added and samples were loaded onto 1.5 ml Dowex AG 50W-X4 columns (pre-washed with 10 ml 1 M HCl followed by 10 ml water) and washed with 2 ml of water. Samples were eluted with 4 ml water onto Alumina columns (pre-washed with 10 ml 0.1 M imidazole at pH 7.5) and washed with 1 ml 0.1 M imidazole at pH 7.5. Then samples were eluted with 4 ml 0.1 M imidazole into scintillation vials, and 4 ml scintillation cocktail (Ultima Flow M) was added to each vial. Samples were counted for 5 min in a Beckman LS600IC using two windows 0–400 and 400–1000. Column efficiency was determined by recovery of ³H-cAMP, and the amount of ³²P-cAMP produced (pmol/min/mg protein) was calculated taking column efficiency into account. H-Ras and Rab3a were purchased from Sigma. K-Ras was from Merck. Radionucleotides were from Amersham and other chemicals from Sigma. All statistical analyses were performed using the paired student's *t*-test. Buffers for all experiments were prepared using Milli-Q purified water (Millipore).

GST fusion protein preparation

Wild-type and mutant NF1-GRD-GST fusion proteins (28) and GST alone were purified using glutathione beads as follows: 1 l cultures of *Escherichia coli* DH5 α cells carrying GST-fusion plasmids were grown in LB plus 100 mg/ml ampicillin at 37°C to log-phase and treated with 1 mM isopropyl- β -D-thiogalactopyranoside for 1 h. Cells were collected and lysed by sonication, at 4°C for six cycles with 20 s each cycle, in 40 ml sonication buffer containing 1 mM EDTA, 1 mM EGTA 0.1% lubrol, 0.1 mM dithiothreitol and protease inhibitor cocktail (Roche). After centrifugation at 15 700g (Beckman JS-13-1) for 30 min at 4°C, ~30 ml of supernatant was added to 1 ml of 50% glutathione beads (Sigma), rotated for 1–2 h at 4°C followed by centrifugation at 735g for 5 min at 4°C. Beads were washed with 10 ml sonication buffer with protease inhibitor cocktail and then washed

with 10 ml elution buffer containing 50 mM Tris, 0.5 mM MgCl₂ and 0.5 mM dithiothreitol. For elution of the protein, 3 ml of elution buffer was added plus 4.2 mg/ml glutathione (Sigma) and supernatants were collected by centrifugation. Proteins were added to the head membrane extracts, at 1 mM concentration, at different time points as described above for Ras. GST-NF1-GRD fusion constructs were provided by F. Tamanoi (University of California, Los Angeles, CA, USA).

Larval brain AC activity assay

About 30 brains per genotype of third instar larvae were dissected in *Drosophila* larval saline solution (70 mM NaCl, 5 mM KCl, 10 mM NaHCO₃, 115 mM sucrose, 5 mM HEPES, 5 mM trehalose, 1.5 mM CaCl₂, 20 mM MgCl₂ at pH 7.1) at room temperature. In order to mimic physiological conditions as closely as possible, brains were dissociated manually into individual neurons in 100 µl larval saline, using forceps and pipetting, than separated into control and experimental groups that were kept on ice while other genotypes were dissected. To minimize variability, control and experimental groups in each comparison were always assayed in the same batch. Results generated from such experiments were highly consistent. Experimental groups were incubated at room temperature, with 2 mM growth factors in 10 mM Tris-acetate (pH 7.5) for 5 min, or with 0.2 mM neurotransmitters in 10 mM Tris-acetate for 2 min, as indicated in methods. Controls were treated with 10 mM Tris-acetate alone for 2–5 min. After incubation, cells were centrifuged at low speed (1800g), then re-suspended in 180 µl lysis buffer (see above), and homogenized for 2 min on ice in an Eppendorf tube using a plastic pestle (Kontes). Protein concentration (typically 2–2.5 mg/ml) was determined using the Bradford Protein Assay (BioRad). Fifty microlitres 2× assay buffer (see above) and 20 µl Ca²⁺ solution (see above) was added to 20 µl samples in glass vials on ice. Samples were equilibrated at 25°C for 2 min, then 10 µl radioactive substrate (see above) was added, and reactions were incubated at 25°C for a further 10 min (growth factors) or 5 min (neurotransmitters). Reactions were stopped, then applied to columns and counted exactly as described for adult heads (see above). Growth factors (mouse EGF, rat TGFα), insulin and neurotransmitters (dopamine, FMRFamide, histamine and serotonin) were purchased from Sigma.

Mutagenesis of hNF1 and cloning of deletion constructs

Clones containing the human *NF1* gene were obtained from A. Bernards (Massachusetts General Hospital). The 88:12 clone is a *NotI*–*SalI* fragment that contains the entire human *NF1* cDNA cloned into *NotI*–*SalI* sites of pBluescript (pBSK; Stratagene). The UAS-*hNF1* clone contains the *NotI*–*SalI* fragment of 88:12 cloned into *NotI*–*XhoI* sites of the pUAST vector, destroying both the *SalI* and *XhoI* site. For this study, a *NotI*–*XhoI* fragment of 88:12 was subcloned into *NotI*–*XhoI* cut pBluescript, and a *XhoI*–*KpnI* fragment of 88:12 was subcloned into *XhoI*–*KpnI* cut pBluescript. Site-directed mutagenesis of the subclones used the Stratagene Chameleon kit with a pBSK-specific phosphorylated selection primer (5' pCGCCACCGCGATGTAGCTCCAATTCG 3')

and mutation-specific mutagenesis primers, which altered a restriction enzyme site in addition to creating the desired clinically identified amino acid mutation (Table 1). Clones were selected by restriction analysis and verified by PCR and sequencing, then mutagenized fragments were digested, gel-purified and ligated into the UAS-*hNF1* construct.

Deletion constructs (Fig. 4A) were generated using restriction digests and other enzymes as noted below, and verified by sequencing and PCR. The UAS-GRD2 construct (residues 986–1746, bases 3153–5432) was prepared by subcloning an *NheI* fragment into the *XbaI* site of pUAST. The UAS-ΔGRD2 construct (deletion 986–1746) was generated by digesting the UAS-*hNF1* clone with *NheI* to remove bases 3153–5432, then digesting single stranded ends with Mung Bean nuclease (New England Biolabs) and re-ligating to restore the hNF1 reading frame. The UAS-GRD1 construct (residues 1241–1746, bases 3918–5432) was prepared by digesting the UAS-GRD2 construct with *XhoI* and re-ligating to remove the *NheI*–*XhoI* fragment (bases 3153–3917). The UAS-Nterm clone (residues 1–985, bases 198–3152) was prepared by digesting UAS-*hNF1* with *NheI* and *XbaI* and re-ligating to remove the GRD and C-terminal regions. The UAS-Cterm clone (residues 1748–2843, bases 5433–8717) was prepared by digesting with *NotI* and *NheI*, end filling with Klenow and re-ligating the blunt ends to remove the N-terminal and GRD regions.

Transgenic flies

P-element-mediated transformations were performed by injecting the mutated UAS-*hNF1* cDNAs and deletion constructs into white^{118(isoCJ1)} (48) *Drosophila* embryos together with pTURBO as a source of transposase (50). DNA used for injection was prepared using Qiagen kits and checked by PCR and restriction analysis. F1 transformants were identified by eye color and the location of insertions was assayed by crossing to the double balancer line *w/Y;CyO/Sp;TM3Ser/Sb* (47). Transcription of UAS-*hNF1* transgenes in flies was controlled using the global Gal4 driver, *e22c-Gal4* and a nervous system-specific X chromosome line, *elav-Gal4* (see above). Second chromosome hNF1 insertion lines and Gal4 driver lines were crossed into the *NF1*^{P2} mutant background using *w/Y;CyO/Sp;TM3Ser/Sb* (47) to create doubly homozygous lines with normal or mutant *hNF1;Nf1*^{P2} or Gal4 driver;*Nf1*^{P2}. The crossing schemes designed to generate progeny carrying one copy of the transgene and one copy of the Gal4 driver in the *Nf1* mutant background are outlined (Fig. 4B and C). Each of the mutant hNF1s and deletion constructs was tested using multiple Gal4 driver lines (in addition to the two presented here) and multiple insertion lines, except for R1276P for which only one transgenic line could be generated (Table 1).

MAP kinase activity

Flies were collected at the same time each day to minimize circadian differences in phospho-MAPK levels (7). For each genotype, 10 heads were homogenized in 75 µl 1× SDS loading buffer (Invitrogen) plus 0.5 mM dithiothreitol and protease inhibitor cocktail (Roche). Samples were run on precast

10% Tris–glycine gels (Novex, Invitrogen) in 1× Tris–glycine–SDS buffer at 125 V for 2 h. Proteins were transferred to nitrocellulose in 1× Novex buffer plus 20% methanol for 2 h at 25 V. Transfer was verified by Ponceau staining, then blots were blocked in 5% milk/TBST for 1 h at room temperature, rinsed for 3 × 5 min in TBST, then probed with primary antibody diluted 1/500 in 5% milk/TBST overnight at 4°C. Rabbit polyclonal antibodies to phosphorylated and non-phosphorylated human p44/42 MAPK were obtained from Cell Signaling Technology. Following rinses of 3 × 5 min in TBST, blots were incubated with 1/10 000 donkey anti-rabbit HRP-conjugated secondary antibody (Amersham) diluted in 5% milk/TBST for 1 h at room temperature, then rinsed again for 3 × 5 min in TBST, followed by 5 min TBS, prior to detection of signal using the ECL kit (Amersham) and multiple timed exposures to X-ray film. Blots were stripped for re-probing using ReBlot (Chemicon). A representative western blot probed with an anti-phospho-MAPK antibody and then stripped and re-probed with anti-MAPK antibody as shown in Figure 4D. Levels of phospho-MAPK and total MAPK were quantified using the densitometric function of the FluorChem imager (Alpha Innotech). After subtraction of in-lane background, levels of phospho-MAPK and total MAPK were normalized relative to control K33 wild-type samples (+) run in parallel on each gel (Fig. 4D). The ratio of phospho-MAPK to MAPK was determined and the results of four to six independent experiments are graphed (Fig. 4E). Expression of full-length hNF1 was confirmed by western blot using a rabbit polyclonal antibody *sc-68* (Santa Cruz) directed against the C-terminal domain of human NF1 (data not shown).

Body size measurement

The normal *hNF1* gene has been shown to partially rescue AC-dependent small body size defects when expressed in the *Nf1* mutant background, using the global Gal4 drivers *armadillo-Gal4* and *e22c-Gal4* (12). In order to improve the statistical power of our body size analysis, we separated males and females for pupal size measurements in this study, as the large difference in body size between the sexes may mask the effects of the transgenes. Body size was assayed by measuring the length of late stage 10 pupae (eye pigments visible); (51) with a digital micrometer (Mitutoyo). Pupae were placed into a 96-well-plate and their sex determined after eclosion of adults. At least 50 pupae of each sex were measured and statistical significance was assessed using a paired student's *t*-test.

ACKNOWLEDGEMENTS

We thank Andre Bernards for providing *Nf1* mutant flies and human NF1 clones. We also thank both Inessa Hakker and Kimberley Weinreich for their excellent technical assistance in the generation of transgenic *Drosophila* lines and mutant hNF1s. This work was supported by a National Neurofibromatosis Foundation Young Investigator Award (F.H.), and by grants from the National Institutes of Health to Y.Z. (NIH 2R01 NS34779-06) and from the US Army Neurofibromatosis

Research Program to F.H. and Y.Z. (DAMD17-99-1-9500), and to F.H. (W81XWH-04-1-025).

Conflict of Interest statement. The authors declare that they have no conflict of interest regarding this manuscript.

REFERENCES

- Riccardi, V.M. (1993) Genotype, malleotype, phenotype, and randomness: lessons from neurofibromatosis-1 (NF-1). *Am. J. Hum. Genet.*, **5**, 301–304.
- North, K.N., Riccardi, V., Samango-Sprouse, C., Ferner, R., Moore, B., Legius, E., Ratner, N., and Denckla, M.B. (1997) Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. *Neurology*, **48**, 1121–1127.
- Gutmann, D.H. (1999) Learning disabilities in neurofibromatosis 1: sizing up the brain. *Arch. Neurol.*, **56**, 1322–1323.
- Cichowski, K., and Jacks, T. (2001) NF1 tumor suppressor gene function: narrowing the GAP. *Cell*, **104**, 593–604.
- Zhu, Y. and Parada, L.F. (2002) The molecular and genetic basis of neurological tumours. *Nat. Rev. Cancer*, **2**, 616–626.
- Costa, R.M. and Silva, A.J. (2003) Mouse models of neurofibromatosis type I: bridging the GAP. *Trends Mol. Med.*, **9**, 19–23.
- Williams, J.A., Su, H.S., Bernards, A., Field, J., and Sehgal, A. (2001) A circadian output in *Drosophila* mediated by neurofibromatosis-1 and Ras/MAPK. *Science*, **293**, 2251–2256.
- The, I., Hannigan, G.E., Cowley, G.S., Reginald, S., Zhong, Y., Gusella, J.F., Hariharan, I.K., and Bernards, A. (1997) Rescue of a *Drosophila* NF1 mutant phenotype by protein kinase A. *Science*, **276**, 791–794.
- Guo, H.F., The, I., Hannan, F., Bernards, A., and Zhong, Y. (1997) Requirement of *Drosophila* NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. *Science*, **276**, 795–798.
- Guo, H.F., Tong, J., Hannan, F., Luo, L., and Zhong Y. (2000) A neurofibromatosis-1-regulated pathway is required for learning in *Drosophila*. *Nature*, **403**, 895–898.
- Kim, H.A., Ratner, N., Roberts, T.M., and Stiles, C.D. (2001) Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. *J. Neurosci.*, **15**, 1110–1116.
- Tong, J., Hannan, F., Zhu, Y., Bernards, A., and Zhong, Y. (2002) Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. *Nat. Neurosci.*, **5**, 95–96.
- Dasgupta, B., Dugan, L.L., and Gutmann, D.H. (2003) The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylyl cyclase-activating polypeptide-mediated signaling in astrocytes. *J. Neurosci.*, **23**, 8949–8954.
- Viskochil, D., White, R., and Cawthon, R. (1993) The neurofibromatosis type 1 gene. *Annu. Rev. Neurosci.*, **16**, 183–205.
- DeClue, J.E., Heffelfinger, S., Benvenuto, G., Ling, B., Li, S., Rui, W., Vass, W.C., Viskochil, D., and Ratner, N. (1992) Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. *Cell*, **69**, 265–273.
- Ingram, D.A., Hiatt, K., King, A.J., Fisher, L., Shivakumar, R., Derstine, C., Wenning, M.J., Diaz, B., Travers, J.B., Hood, A. *et al.* (2001) Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells *in vivo* and *in vitro*. *J. Exp. Med.*, **194**, 57–69.
- Costa, R.M., Yang, T., Huynh, D.P., Pulst, S.M., Viskochil, D.H., Silva, A.J., and Brannan, C.I. (2001) Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. *Nat. Genet.*, **27**, 399–405.
- Costa, R.M., Federov, N.B., Kogan, J.H., Murphy, G.G., Stern, J., Ohno, M., Kucherlapati, R., Jacks, T., and Silva, A.J. (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. *Nature*, **415**, 526–530.
- Bos, J.L. (1990) *ras* oncogenes in human cancer: a review. *Cancer Res.*, **49**, 4682–4689.

20. Bernards, A. (2003) GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and *Drosophila*. *Biochim. Biophys. Acta*, **1603**, 47–82.
21. Gaul, U., Mardon, G., and Rubin, G.M. (1992) A putative Ras GTPase activating protein acts as a negative regulator of signaling by the Sevenless receptor tyrosine kinase. *Cell*, **68**, 1007–1019.
22. Powe, A.C. Jr., Strathdee, D., Cutforth, T., D'Souza-Correia, T., Gaines, P., Thackeray, J., Carlson, J., and Gaul, U. (1999) *In vivo* functional analysis of *Drosophila* Gap1: involvement of Ca²⁺ and IP4 regulation. *Mech. Dev.*, **81**, 89–101.
23. Quilliam, L.A., Rebhun, J.F., and Castro, A.F. (2002) A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. *Prog. Nucl. Acid Res. Mol. Biol.*, **71**, 391–444.
24. Rommel, C. and Hafen, E. (1998) Ras—a versatile cellular switch. *Curr. Opin. Genet. Dev.*, **8**, 412–418.
25. Simon, M.A., Bowtell, D.D., Dodson, G.S., Laverty, T.R., and Rubin, G.M. (1991) Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. *Cell*, **67**, 701–716.
26. Schlessinger, J. (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. *Cell*, **110**, 669–672.
27. Jorissen, R.N., Walker, F., Pouliot, N., Garrett, T.P., Ward, C.W., and Burgess, A.W. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. *Exp. Cell Res.*, **284**, 31–53.
28. Kim, M.R. and Tamanoi, F. (1998) Neurofibromatosis 1 GTPase activating protein-related domain and its functional significance. In Upadhyaya, M. and Cooper, D.N. (eds.), *Neurofibromatosis Type 1 from Genotype to Phenotype*. Bios Scientific Publishers, Oxford, UK, Washington, DC, pp. 89–112.
29. Gutmann, D.H., Boguski, M., Marchuk, D., Wigler, M., Collins, F.S., and Ballester, R. (1993) Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis. *Oncogene*, **8**, 761–769.
30. Upadhyaya, M., Osborn, M.J., Maynard, J., Kim, M.R., Tamanoi, F., and Cooper, D.N. (1997) Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. *Hum. Genet.*, **99**, 88–92.
31. Clifford, R. and Schupbach, T. (1994) Molecular analysis of the *Drosophila* EGF receptor homolog reveals that several genetically defined classes of alleles cluster in subdomains of the receptor protein. *Genetics*, **137**, 531–550.
32. Wolfgang, W.J., Hoskote, A., Roberts, I.J., Jackson, S., and Forte, M. (2001) Genetic analysis of the *Drosophila* Gs(alpha) gene. *Genetics*, **158**, 1189–1201.
33. Bogdan, S. and Klambt, C. (2001) Epidermal growth factor receptor signaling. *Curr. Biol.*, **11**, R292–R295.
34. Fahsold, R., Hoffmeyer, S., Mischung, C., Gille, C., Ehlers, C., Kucukceylan, N., Abdel-Nour, M., Gewies, A., Peters, H., Kaufmann, D. *et al.* (2000) Minor lesion mutational spectrum of the entire *NF1* gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. *Am. J. Hum. Genet.*, **66**, 790–818.
35. Messiaen, L.M., Callens, T., Mortier, G., Beysen, D., Vandenbroucke, I., Van Roy, N., Speleman, F., and Paeppe, A.D. (2000) Exhaustive mutation analysis of the *NF1* gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. *Hum. Mutat.*, **15**, 541–555.
36. Serra, E., Ars, E., Ravella, A., Sanchez, A., Puig, S., Rosenbaum, T., Estivill, X., and Lazaro, C. (2001) Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. *Hum. Genet.*, **108**, 416–429.
37. Pouillet, P., Lin, B., Esson, K., and Tamanoi, F. (1994) Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes. *Mol. Cell. Biol.*, **14**, 815–821.
38. Klose, A., Ahmadian, M.R., Schuelke, M., Scheffzek, K., Hoffmeyer, S., Gewies, A., Schmitz, F., Kaufmann, D., Peters, H., Wittinghofer, A., and Nurnberg, P. (1998) Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. *Hum. Mol. Genet.*, **7**, 1261–1268.
39. Brand, A.H. and Perrimon, N. (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development*, **118**, 401–415.
40. Duffy, J.B., Harrison, D.A., and Perrimon, N. (1998) Identifying loci required for follicular patterning using directed mosaics. *Development*, **125**, 2263–2271.
41. Lin, D.M. and Goodman, C.S. (1994) Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. *Neuron*, **13**, 507–523.
42. Sunahara, R.K. and Taussig, R. (2002) Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. *Mol. Interv.*, **2**, 168–184.
43. Beckner, S.K., Hattori, S., and Shih, T.Y. (1985) The ras oncogene product p21 is not a regulatory component of adenylate cyclase. *Nature*, **317**, 71–72.
44. Birchmeier, C., Broek, D., Toda, T., Powers, S., Kataoka, T., and Wigler, M. (1985) Conservation and divergence of RAS protein function during evolution. *Cold Spring Harbor Symp. Quant. Biol.*, **50**, 721–725.
45. Sun, H., Seyer, J.M., and Patel, T.B. (1995) A region in the cytosolic domain of the epidermal growth factor receptor antithetically regulates the stimulatory and inhibitory guanine nucleotide-binding regulatory proteins of adenylyl cyclase. *Proc. Natl Acad. Sci. USA*, **92**, 2229–2233.
46. Stryjek-Kaminska, D., Piiper, A., and Zeuzem, S. (1996) Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1-2 proteins in pancreatic acinar membranes. *Biochem. J.*, **316**, 87–91.
47. Lindsley, D.L. and Zimm, G.G. (1992) *The Genome of Drosophila melanogaster*. Academic Press, San Diego, CA, USA.
48. Yin, J.C., Wallach, J.S., Del Vecchio, M., Wilder, E.L., Zhou, H., Quinn, W.G., and Tully, T. (1994) Induction of a dominant negative CREB transgene specifically blocks long-term memory in *Drosophila*. *Cell*, **79**, 49–58.
49. Livingstone, M.S. (1985) Genetic dissection of *Drosophila* adenylate cyclase. *Proc. Natl Acad. Sci. USA*, **82**, 5992–5996.
50. Rubin, G.M. and Spradling, A.C. (1982) Genetic transformation of *Drosophila* with transposable element vectors. *Science*, **218**, 348–353.
51. Bainbridge, S.P. and Bownes, M. (1981) Staging the metamorphosis of *Drosophila melanogaster*. *J. Embryol. Exp. Morphol.*, **66**, 57–80.